These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34209595)

  • 21. Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.
    Fox KAA; Lucas JE; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Hacke W; Kayani G; Oto A; Mantovani LG; Misselwitz F; Piccini JP; Turpie AGG; Verheugt FWA; Kakkar AK;
    BMJ Open; 2017 Dec; 7(12):e017157. PubMed ID: 29273652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
    Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
    Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design.
    De Caterina R; Agnelli G; Laeis P; Unverdorben M; Rauer H; Wang CC; Nakamura M; Chiu KM; Reimitz PE; Koretsune Y; Chen C; Thee U; Kaburagi J; Kim YH; Choi WI; Yamashita T; Cohen A; Kirchhof P
    Clin Cardiol; 2019 Dec; 42(12):1147-1154. PubMed ID: 31650560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
    Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
    Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial.
    De Caterina R; Renda G; Carnicelli AP; Nordio F; Trevisan M; Mercuri MF; Ruff CT; Antman EM; Braunwald E; Giugliano RP
    J Am Coll Cardiol; 2017 Mar; 69(11):1372-1382. PubMed ID: 28302288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation: One-Year Data from the Global ETNA-AF Program.
    Chao TF; Unverdorben M; Kirchhof P; Koretsune Y; Yamashita T; Crozier RA; Pecen L; Chen C; Borrow AP; De Caterina R
    J Clin Med; 2023 Feb; 12(5):. PubMed ID: 36902656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
    Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
    Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
    Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
    Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
    Kato ET; Giugliano RP; Ruff CT; Koretsune Y; Yamashita T; Kiss RG; Nordio F; Murphy SA; Kimura T; Jin J; Lanz H; Mercuri M; Braunwald E; Antman EM
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stroke prevention in atrial fibrillation patients in Poland and other European countries: insights from the GARFIELD-AF registry.
    Stępińska J; Kremis E; Konopka A; Wożakowska-Kapłon B; Ruszkowski P; Kukla P; Kayani G
    Kardiol Pol; 2016; 74(4):362-71. PubMed ID: 26365937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and safety of dabigatran versus acenocoumarol in 'real-world' patients with atrial fibrillation.
    Korenstra J; Wijtvliet EP; Veeger NJ; Geluk CA; Bartels GL; Posma JL; Piersma-Wichers M; Van Gelder IC; Rienstra M; Tieleman RG
    Europace; 2016 Sep; 18(9):1319-27. PubMed ID: 26843571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial.
    Magnuson EA; Vilain K; Wang K; Li H; Kwong WJ; Antman EM; Ruff CT; Giugliano RP; Cohen DJ;
    Am Heart J; 2015 Dec; 170(6):1140-50. PubMed ID: 26678636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Management of thromboembolic risk in patients with atrial fibrillation in Italy: follow-up data from the PREFER in AF European Registry].
    Renda G; Patti G; Sangiuolo R; Attena E; Malpezzi MG; De Caterina R;
    G Ital Cardiol (Rome); 2016 Nov; 17(11):922-931. PubMed ID: 27996998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry.
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli G; Reiffel J; Singer DE; Peterson ED; Piccini JP;
    J Am Coll Cardiol; 2016 Dec; 68(24):2597-2604. PubMed ID: 27978942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Wide Variation in Reported Rates of Stroke Across Cohorts of Patients With Atrial Fibrillation.
    Quinn GR; Severdija ON; Chang Y; Singer DE
    Circulation; 2017 Jan; 135(3):208-219. PubMed ID: 27799272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
    De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
    Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Net Clinical Benefit of Edoxaban for Stroke, Mortality, and Bleeding Risk: Modeling Projections for a European Population.
    Blann AD; Pisters R; Lip GYH
    JACC Clin Electrophysiol; 2016 Feb; 2(1):47-54. PubMed ID: 29766853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The thromboembolism risk of low-risk atrial fibrillation patients with different clinical characteristics].
    Liu XB; Jia ZX; Xia SJ; He L; Lu SX; Guo XY; Li SN; Liu N; Jiang CX; Sang CH; Tang RB; Long DY; Yu RH; Bai R; Wu JH; Du X; Dong JZ; Ma CS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Sep; 48(9):735-739. PubMed ID: 32957755
    [No Abstract]   [Full Text] [Related]  

  • 40. Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.
    Tsai CT; Liao JN; Chiang CE; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chung FP; Chao TF; Lip GYH; Chen SA
    JAMA Netw Open; 2020 Jun; 3(6):e206424. PubMed ID: 32478848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.